eligibility_summary
Eligibility: ≥14 yrs, CD19+ B‑ALL post‑allogeneic HSCT, pre‑HSCT high‑risk (refractory/relapsed, WBC>30×10^9/L, poor cytogenetics, or MRD+). Must be in CR, MRD‑negative with ANC≥1.0×10^9/L and platelets≥50×10^9/L >1 week, no ≥grade 3 acute or uncontrolled mod‑severe chronic GVHD in past 30 days, consent. Exclude: post‑HSCT relapse/MRD+, uncontrolled infection, major liver/renal labs, active HBV/HCV/HIV/syphilis, CrCl<70, ECOG≥3, survival<3 mo, or per investigator.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Single-arm maintenance after allo-HCT in high-risk CD19+ B-ALL: blinatumomab given in 4 cycles starting ~3 months post-transplant (continuous infusion 9 µg/d days 1–4, then 28 µg/d days 5–14 per cycle), with optional TKI. Blinatumomab is a bispecific T-cell engager (BiTE) biologic that binds CD19 on B-lineage leukemia cells and CD3 on T cells, redirecting cytotoxic T cells to eliminate CD19+ cells/MRD. The optional TKI is a small-molecule tyrosine kinase inhibitor used when indicated to block oncogenic kinase signaling (e.g., BCR-ABL1 in Ph+ disease). Targets: CD19+ B blasts, CD3+ T-cell activation, tyrosine kinase pathways.